Bristol Myers Squibb (CELG-RI) Net Margin (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Net Margin of 25.56% for Q2 2026, up 1486.0% year-over-year from 1.61% in Q2 2025, and up 9.62% quarter-over-quarter from 23.32% in Q1 2026.
Bristol Myers Squibb (CELG-RI) Net Margin (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Net Margin for 18 consecutive years, with 25.56% the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Margin rose 1486.0% year-over-year to 25.56%; the TTM figure through Jun 2026 stood at 18.86% (up 824.0% YoY), while the FY2025 annual figure was 14.64%, up 3314.0% from the prior year.
- Net Margin climbed to 25.56% in Q2 2026 per CELG-RI's latest filing, from 23.32% in the prior quarter.
- Across five years, Net Margin topped out at 25.56% in Q2 2026 and bottomed at 100.36% in Q1 2024.
- Historically, Net Margin has averaged 8.84% across 5 years, with a median of 14.84% in 2022.
- Annual changes were most pronounced in 2024 — Net Margin plunged 12036 bps — and 2025, when it surged 12234 bps.
- Bristol Myers Squibb's Net Margin stood at 17.75% in 2022, then dropped by 14 bps to 15.35% in 2023, then plunged by 96 bps to 0.62% in 2024, then jumped by 1311 bps to 8.69% in 2025, then soared by 194 bps to 25.56% in 2026.
- Business Quant data shows CELG-RI's Net Margin at 25.56% in Q2 2026, 23.32% in Q1 2026, and 8.69% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 21.86% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -8.05% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 22.65% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 16.30% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 23.62% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -134.51% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -1.58% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 5.17% |
| 10 | Bristol Myers Squibb | 188.27 Mn | -10.88 Bn | 9.25 Bn | 25.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.56% |
| Mar 31, 2026 | 23.32% |
| Dec 31, 2025 | 8.69% |
| Sep 30, 2025 | 17.96% |
| Jun 30, 2025 | 10.70% |
| Mar 31, 2025 | 21.98% |
| Dec 31, 2024 | 0.62% |
| Sep 30, 2024 | 10.22% |
| Jun 30, 2024 | 13.80% |
| Mar 31, 2024 | -100.36% |
| Dec 31, 2023 | 15.35% |
| Sep 30, 2023 | 17.64% |
| Jun 30, 2023 | 18.50% |
| Mar 31, 2023 | 20.00% |
| Dec 31, 2022 | 17.75% |
| Sep 30, 2022 | 14.33% |
| Jun 30, 2022 | 12.02% |
| Mar 31, 2022 | 11.01% |
| Dec 31, 2021 | 19.79% |
| Sep 30, 2021 | 13.35% |